title: An Improvement of the Efficacy of Moxifloxacin HCl for the Treatment of Bacterial Keratitis by the Formulation of Ocular Mucoadhesive Microspheres.
abstract: The aim of this study was to prepare novel ocular mucoadhesive microspheres of Moxifloxacin HCl to increase its residence time on the ocular surface and to enhance its therapeutic efficacy in ocular bacterial keratitis. Microspheres were fabricated with different grades of Methocel and Sodium CMC as polymers. Microspheres were evaluated for their particle size, morphology, encapsulation efficiency, mucoadhesion, antimicrobial efficacy, and in vitro drug release studies. In vivo studies were carried out for the promising formulation on eyes of albino rabbits by inducing bacterial keratitis. A sterile microspheres suspension in light mineral oil was applied to infected eyes twice a day. A marketed conventional eye drop was used as a positive control. Eyes were examined daily for improvement of clinical signs of bacterial keratitis by an ophthalmologist. The average particle size of microspheres was found to be less than 80 μm. Methocel microspheres were found to have a smoother surface than Sodium CMC. Entrapment efficiency was enhanced with an increased polymer concentration and viscosity. The formulation containing Methocel K100M with a drug: polymer ratio of 1:2 exerted longer corneal and conjunctival mucoadhesion time of 8.45±0.15 h and 9.40±0.53 h respectively. In vitro release of Moxifloxacin HCl from microspheres was retarded with increased viscosity and concentration of polymers, and was controlled by diffusion as well as polymer relaxation. All formulations showed comparable antimicrobial activity in comparison with conventional marketed eye drops. The formulation containing Methocel K100M with a drug: polymer ratio of 1:2 was found to be a promising formulation and was used for the in vivo studies. The in vivo studies revealed that microspheres demonstrated significantly lower clinical scores and reduced the total duration of therapy than the marketed Moxifloxacin HCl eye drops. In vitro and in vivo studies showed that ocular mucoadhesive microspheres of Moxifloxacin HCl were found to have an improved efficacy in the treatment of ocular bacterial keratitis in comparison with the marketed formulation.
authors: KLE University's College of Pharmacy, JNMC Campus, Nehru nagar, 590010, Belgaum, India.
authors: Panchaxari Mallappa
authors: PM
authors: Dandagi
authors: Amit Manohar
authors: AM
authors: Belekar
authors: Vinayak Shivamurthy
authors: VS
authors: Mastiholimath
authors: Anand Panchakshari
authors: AP
authors: Gadad
authors: Vivek Wamanrao
authors: VW
authors: Sontake
authors: Prashant Sanjivrao
authors: PS
authors: Salian
keywords: Bacterial keratitis; Microspheres; Moxifloxacin HCl; Mucoadhesion; Ocular
references: Ophthalmology. 2007 Sep;114(9):1622-9
references: 17822972
references: Nanomedicine. 2010 Apr;6(2):324-33
references: 19857606
references: Am J Ophthalmol. 2006 Nov;142(5):721-5
references: 16989762
references: Clin Ther. 2008 Nov;30(11):2005-14
references: 19108788
references: Surv Ophthalmol. 2005 Nov;50 Suppl 1:S32-45
references: 16257309
references: J Pharm Sci. 2003 Feb;92(2):407-13
references: 12532390
references: Acta Pharm. 2010 Sep;60(3):349-60
references: 21134868
references: Clin Ther. 1995 Sep-Oct;17(5):800-10; discussion 779
references: 8595633
references: Cornea. 2008 Jan;27(1):22-7
references: 18245962
references: Med J Armed Forces India. 2003 Jul;59(3):239-41
references: 27407524
references: Int J Pharm. 2007 Oct 1;343(1-2):34-40
references: 17537601
references: Adv Drug Deliv Rev. 2005 Nov 3;57(11):1595-639
references: 16198021
references: Eur J Pharm Sci. 2001 May;13(2):123-33
references: 11297896
references: Int J Pharm. 2011 Oct 10;418(1):6-12
references: 21458553
references: Saudi Pharm J. 2011 Jul;19(3):143-52
references: 23960752
references: J Ethnopharmacol. 2003 Jan;84(1):1-4
references: 12499068
references: Int J Pharm. 2006 Jul 24;317(2):127-35
references: 16624509